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I n this issue of Anesthesiology, Uhlig et al.1 compare morbid-
ity and mortality with volatile 
anesthetics versus total intravenous 
anesthesia in a comprehensive 
meta-analysis of 68 published ran-
domized controlled trials (RCts) 
that included 7104 patients. The 
authors found that outcomes in 
patients undergoing cardiac sur-
gery were different from outcomes 
in other patient groups, and they 
stratified their results accordingly. 
The primary endpoint was mortal-
ity, defined as the longest mortal-
ity reported, in-hospital or 30-day 
mortality. The secondary endpoints 
were pulmonary and other compli-
cations. Volatile anesthetics were 
associated with reduced mortality 
and postoperative complications in 
patients undergoing cardiac surgery 
when compared with intravenous 
anesthesia. however, the choice of 
anesthetic did not influence mor-
tality or postoperative complica-
tions for other types of surgery.
We congratulate the authors 
for this fine analysis. They care-
fully researched three databases, complying meticulously 
with the Preferred Reporting items for systematic Reviews 
and Meta-Analyses guidelines. The topic addressed is sci-
entifically interesting and clinically relevant. The results 
bring together a large number of trials addressing the ques-
tion of organ protection. given the comprehensiveness of 
this analysis, the high quality of the RCts analyzed, and the 
meticulous statistical treatment of the results, perhaps Uhl-
man et al. have published the definitive analysis. however, 
the authors suggest that more research is needed.
For a proper interpretation of studies suggesting immu-
nomodulation by volatile anesthetics improving clinical out-
come, the following issues deserve careful evaluation:
1. some studies have been per-
formed in scenarios of a “hit,” 
e.g., ischemia–reperfusion injury 
in transplantation or cardiac sur-
gery with extracorporeal circula-
tion, while in other studies, such 
events remain elusive. one has to 
acknowledge the fact that there is 
no protection from an injury, if 
there is no injury. Additionally, 
the degree of injury certainly mat-
ters, which could explain the find-
ings of the current study.1
2. The mode of application of 
volatile anesthetics may play an 
important role. The authors did not 
differentiate between administering 
volatile anesthetics for the entire 
duration of surgery and a “pre-con-
ditioning” application, where the 
anesthetic was applied right before 
the ischemic injury. obviously, 
such an application is very clear 
during cardiac surgery, but much 
less so in other types of surgery that 
do not involve a specific ischemic 
challenge. subtle details like these 
may well impact outcome.
3. The authors have reasonably 
grouped together all volatile anesthetics. While that makes 
sense, we do not know if isoflurane, sevoflurane, and des-
flurane are equally protective. Uhlig et al.1 point out that 
sevoflurane and desflurane seemed more protective than iso-
flurane in cardiac surgery patients.
4. We should bear in mind that most of the clinical studies 
have focus on biomarkers such as troponin, transaminases, 
creatinine, inflammatory mediators, or markers of cell death. 
The power analysis has been performed with regard to such 
surrogate markers, while the studies with clinically relevant 
outcomes are few and far between.
5. Additionally, we notice that even when relevant clinical 
outcomes are reported, they are frequently not presented 
“We know that in the 
 published studies for 
 cardiac surgery,  assignment 
to  volatile anesthesia gives 
better outcomes than 
 assignment to propofol. 
We don’t know why.”
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Editorial Views
using a well-defined scoring system. The definition of “pul-
monary infection” for example seems to vary from study to 
study and does not allow serving as an operation endpoint.
6. since the RCts in this study compared volatile anesthetics 
to propofol, we naturally attribute differences in outcomes 
to the anesthetics. however, the strength of the RCt design 
is that differences in outcome are causally linked to assign-
ment to a treatment group. The RCt design does not tell us 
why one group did better than the other. The authors natu-
rally attributed the better outcomes with inhaled anesthetics 
for cardiac surgery to the pharmacology of volatile anesthet-
ics. Maybe, but that is a guess. The better outcomes might 
be caused by differences in physician experience with the 
assigned treatment, differences in anesthetic depth between 
the two approaches, differences in other drugs (e.g., how 
many patients get inhaled anesthetics and remifentanil?), 
effects of propofol on the bypass circuit,2 or other nonphar-
macologic differences between the two groups. We know 
that in the published RCts for cardiac surgery, assignment 
to volatile anesthesia gives better outcomes than assignment 
to propofol. We do not know why.
several limitations are discussed by the authors. First, 
negative results are less likely to be published. This truism 
remains a major problem with clinical trials and refuses to 
go away.3 We cannot blame journals, readers, or authors for 
this. it is intrinsic to science that a small trial with a positive 
result is exciting and gets published, but an equally small 
trial with no result has no chance of publication. Consider 
the recent demonstration of gravity waves, based on four 
observations (two events at two observatories).4 This is likely 
one of the most important scientific discoveries in human 
history, and certainly within our lifetime. however, there 
is no chance that more than 1000 coauthors would have 
chosen to write a paper if there had been no observations 
for several months at the two observatories. We rightly ask 
authors, and journals, to be more receptive to negative trials. 
however, it is the nature of science that it takes only one 
observation to prove that something exists, but no amount 
of data can prove something does not exist.
The authors also point out that elements of anesthesia 
such as opioids, local anesthetics used for regional anesthe-
sia, statins, etc., are protective as well and constitute power-
ful confounders. These are rarely reported in sufficient detail 
in RCts for a meta-analysis to fully account for these con-
founding variables. For example, remifentanil infusions are 
commonly used with propofol, but will be only rarely used 
with an inhaled anesthetic. Perhaps the worse outcome in 
the cardiac surgery patients with propofol is because of the 
remifentanil. We are not seriously suggesting this, but simply 
using this to observe that confounding variables involving 
other drugs are likely not to be randomly divided between 
the two techniques.
Uhlig et al., an experienced group of researchers in the 
field of organ protection, summarize their conclusions 
with the adage “further studies are warranted.” is this really 
what we need? The two authors of this editorial have dif-
ferent opinions about this conclusion. one believes that 
it would be quite reasonable to use this meta-analysis as a 
basis to design a definitive clinical trial (B.B.s.). if we want 
to have evidence-based protocols for the patients entrusted 
to us for optimal care, we urgently need large RCts focus-
ing on well-defined clinical endpoints such as complica-
tions and mortality. or, stated differently, we still have not 
reached evidence level i yet.5 The enthusiasm of the second 
author of the editorial, however, is tempered by many stud-
ies summarized in the systematic review that demonstrate 
little difference in outcome between propofol and volatile 
anesthesia (s.l.s.). given the work that has been done, 
and the intrinsic limitations of clinical studies (e.g., item 
6 above), the conclusion is slightly different: “are further 
studies warranted?”
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